Ligand Pharmaceuticals Inc (LGNZZ) — 10-Q Filings
All 10-Q filings from Ligand Pharmaceuticals Inc. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Ligand Pharma Swings to Profit on Soaring Revenue, Strategic Investments
— Nov 7, 2025 Risk: medium
LIGAND PHARMACEUTICALS INCORPORATED (LGND) reported a significant turnaround for the quarter ended September 30, 2025, with net income soaring to $117.27 millio -
Ligand Pharma's Revenue Plunges 40% Amid Royalty and Captisol Declines
— Aug 8, 2025 Risk: high
LIGAND PHARMACEUTICALS INC (LGNZZ) reported a significant decrease in total revenues for the three months ended June 30, 2025, falling to $15.0 million from $25 -
Ligand Pharmaceuticals Q1 2025 Update
— May 9, 2025 Risk: medium
Ligand Pharmaceuticals Inc. reported its first quarter 2025 results, ending March 31, 2025. The company's filing details its financial performance and operation -
Ligand Pharmaceuticals Q3 2024 Update
— Nov 8, 2024 Risk: medium
Ligand Pharmaceuticals Inc. reported its third-quarter 2024 results, ending September 30, 2024. The company's financial statements reflect its ongoing operation -
Ligand Pharmaceuticals Q2 2024 Update
— Aug 7, 2024 Risk: medium
Ligand Pharmaceuticals Inc. reported its second quarter 2024 results, ending June 30, 2024. The company's filing details its financial performance and operation -
Ligand Pharmaceuticals Inc. Files 10-Q for Q1 2024
— May 8, 2024 Risk: medium
LIGAND PHARMACEUTICALS INC (LGNZZ) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Ligand Pharmaceuticals Inc. reported its Q1 2024 financial resul
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX